Cargando…

Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery

BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients undergoing coronary artery bypass grafting (CABG) surgery. The aim of this study was to evaluate the impact of DM on the early- and long-term outcomes of patients who underwent isolated CABG. METHODS: We performed an...

Descripción completa

Detalles Bibliográficos
Autores principales: Kogan, Alexander, Ram, Eilon, Levin, Shany, Fisman, Enrique Z., Tenenbaum, Alexander, Raanani, Ehud, Sternik, Leonid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264047/
https://www.ncbi.nlm.nih.gov/pubmed/30497472
http://dx.doi.org/10.1186/s12933-018-0796-7
_version_ 1783375406103003136
author Kogan, Alexander
Ram, Eilon
Levin, Shany
Fisman, Enrique Z.
Tenenbaum, Alexander
Raanani, Ehud
Sternik, Leonid
author_facet Kogan, Alexander
Ram, Eilon
Levin, Shany
Fisman, Enrique Z.
Tenenbaum, Alexander
Raanani, Ehud
Sternik, Leonid
author_sort Kogan, Alexander
collection PubMed
description BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients undergoing coronary artery bypass grafting (CABG) surgery. The aim of this study was to evaluate the impact of DM on the early- and long-term outcomes of patients who underwent isolated CABG. METHODS: We performed an observational cohort study in a large tertiary medical center over a period of 11 years. All data from patients who had undergone isolated CABG surgery between 2004 and 2014 were obtained from our departmental database. The study population included 2766 patients who were divided into two groups: Group I (1553 non-diabetic patients), and Group II (1213 patients suffering from type 2 DM). Group II patients were then divided into two subgroups: subgroup IIA (981 patients treated with oral antihyperglycemic medications) and subgroup IIB (232 insulin-treated patients with or without additional oral antihyperglycemic drugs). In-hospital, 1-, 3-, 5- and 10-year mortality outcome variables were evaluated. Mean follow-up was 97 ± 41 months. RESULTS: In-hospital mortality was similar between Group I and Group II patients (1.87% vs. 2.31%, p = 0.422) and between the subgroups IIA and IIB (2.14% vs. 3.02%, p = 0.464). Long-term mortality (1, 3, 5 and 10 years) was higher in Group II (DM type 2) compared with Group I (non-diabetic patients) (5.3% vs. 3.6%, p = 0.038; 9.3% vs. 5.6%, p < 0.001; 15.3% vs. 9.3%, p < 0.001 and 47.3% vs. 29.6% p < 0.001). Kaplan–Meier analysis demonstrated that all-cause mortality was higher in Group II compared with Group I (p < 0.001) and in subgroup IIB compared with subgroup IIA (p = 0.001). Multivariable analysis showed that DM increased the mortality hazard by twofold, and among diabetic patients, insulin treatment increased the mortality hazard by twofold. CONCLUSIONS: Diabetic and non-diabetic patients have similar in-hospital mortality rates. Survival rates of diabetic patients start to deteriorate 3 year after surgery. Type 2 DM is an independent predictor for long-term mortality after isolated CABG surgery. Mortality is even higher when the diabetes treatment strategy included insulin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0796-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6264047
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-62640472018-12-05 Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery Kogan, Alexander Ram, Eilon Levin, Shany Fisman, Enrique Z. Tenenbaum, Alexander Raanani, Ehud Sternik, Leonid Cardiovasc Diabetol Original Investigation BACKGROUND: Type 2 diabetes mellitus (DM) is a frequent co-morbidity among patients undergoing coronary artery bypass grafting (CABG) surgery. The aim of this study was to evaluate the impact of DM on the early- and long-term outcomes of patients who underwent isolated CABG. METHODS: We performed an observational cohort study in a large tertiary medical center over a period of 11 years. All data from patients who had undergone isolated CABG surgery between 2004 and 2014 were obtained from our departmental database. The study population included 2766 patients who were divided into two groups: Group I (1553 non-diabetic patients), and Group II (1213 patients suffering from type 2 DM). Group II patients were then divided into two subgroups: subgroup IIA (981 patients treated with oral antihyperglycemic medications) and subgroup IIB (232 insulin-treated patients with or without additional oral antihyperglycemic drugs). In-hospital, 1-, 3-, 5- and 10-year mortality outcome variables were evaluated. Mean follow-up was 97 ± 41 months. RESULTS: In-hospital mortality was similar between Group I and Group II patients (1.87% vs. 2.31%, p = 0.422) and between the subgroups IIA and IIB (2.14% vs. 3.02%, p = 0.464). Long-term mortality (1, 3, 5 and 10 years) was higher in Group II (DM type 2) compared with Group I (non-diabetic patients) (5.3% vs. 3.6%, p = 0.038; 9.3% vs. 5.6%, p < 0.001; 15.3% vs. 9.3%, p < 0.001 and 47.3% vs. 29.6% p < 0.001). Kaplan–Meier analysis demonstrated that all-cause mortality was higher in Group II compared with Group I (p < 0.001) and in subgroup IIB compared with subgroup IIA (p = 0.001). Multivariable analysis showed that DM increased the mortality hazard by twofold, and among diabetic patients, insulin treatment increased the mortality hazard by twofold. CONCLUSIONS: Diabetic and non-diabetic patients have similar in-hospital mortality rates. Survival rates of diabetic patients start to deteriorate 3 year after surgery. Type 2 DM is an independent predictor for long-term mortality after isolated CABG surgery. Mortality is even higher when the diabetes treatment strategy included insulin. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0796-7) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-29 /pmc/articles/PMC6264047/ /pubmed/30497472 http://dx.doi.org/10.1186/s12933-018-0796-7 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Kogan, Alexander
Ram, Eilon
Levin, Shany
Fisman, Enrique Z.
Tenenbaum, Alexander
Raanani, Ehud
Sternik, Leonid
Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
title Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
title_full Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
title_fullStr Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
title_full_unstemmed Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
title_short Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
title_sort impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6264047/
https://www.ncbi.nlm.nih.gov/pubmed/30497472
http://dx.doi.org/10.1186/s12933-018-0796-7
work_keys_str_mv AT koganalexander impactoftype2diabetesmellitusonshortandlongtermmortalityaftercoronaryarterybypasssurgery
AT rameilon impactoftype2diabetesmellitusonshortandlongtermmortalityaftercoronaryarterybypasssurgery
AT levinshany impactoftype2diabetesmellitusonshortandlongtermmortalityaftercoronaryarterybypasssurgery
AT fismanenriquez impactoftype2diabetesmellitusonshortandlongtermmortalityaftercoronaryarterybypasssurgery
AT tenenbaumalexander impactoftype2diabetesmellitusonshortandlongtermmortalityaftercoronaryarterybypasssurgery
AT raananiehud impactoftype2diabetesmellitusonshortandlongtermmortalityaftercoronaryarterybypasssurgery
AT sternikleonid impactoftype2diabetesmellitusonshortandlongtermmortalityaftercoronaryarterybypasssurgery